News – Page 675 – Endpoints News

SIGN UP

The wild card: Just how much is Medivation’s talazoparib worth?

6 years ago

It’s not easy being 5th: Pfizer and Merck KGaA blueprint a new attack on ovarian cancer

6 years ago

Trendy Moderna's single-asset CF pact with Vertex marks a new phase of dealmaking

6 years ago

Biotech IPOs may still be a bright spot, but the light has dimmed

6 years ago

Using money honey instead of threats, Sanofi wins a seat at the bargaining table for Medivation buyout

6 years ago

XBiotech shares tank after PhIII data get a roasting

6 years ago

Pfizer sets up Bind auction with $20M stalking horse bid

6 years ago

Death watch: Epirus Bio joins the growing list of biotech failures headed for the scrap heap

6 years ago

Takeda hands TiGenix a rare, $434M marketing deal for PhIII stem cell therapy

6 years ago

Bristol-Myers bags a new tumor microenvironment drug for next-gen cancer combos

6 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2016

6 years ago

AstraZeneca shuffles the deck, deals out a new hand for two troubled drugs

6 years ago

Kleiner Perkins is lining up a new $400M tech fund

6 years ago

Fresh from Epirus disaster, Munshi chops staff to remake Arena Pharma

6 years ago

Exorcising Martin Shkreli’s ghost, KaloBios steps out of Ch. 11 and back into the biotech business

6 years ago

Ampio shares are routed (again) as its PhIII do-over for osteoarthritis flops

6 years ago

Where the money is: Biotech’s megahubs command VC's billions

6 years ago

Boehringer Ingelheim axes 725 jobs in U.S. reorganization

6 years ago

One of Shire’s top pipeline prospects fails a PhII study among preemies

6 years ago

Bruised but standing, Syros braves its way through a $50M IPO

6 years ago

Novartis shoots for early OK of a ‘breakthrough’ blood cancer drug after reversing organ damage in trial

6 years ago

The biotech IPO feast flags as investors lose their appetite for R&D risk

6 years ago

What PDUFA date? Clovis shares surge as PARPs get trendy on Wall Street

6 years ago

Neoantigens beckon Merck into a $200M cancer collaboration with Moderna

6 years ago

First page Previous page 672 673 674675676 677 Next page Last page